JSON Feed = https://data.pengana.com/wp-json/pen/performance?investment_id=2805
$investpost_id=2805
New $p_investpost_id=31526

The High Conviction Equities Fund invests in a concentrated, ethically screened portfolio of not more than 20 Australian and global companies.

The Fund’s broad asset allocation ranges provide the flexibility to respond to changing markets.

The Fund seeks to identify companies that are significantly undervalued using fundamental analysis.

5 Characteristics of our stocks

Strong competitive position.

leading technology
high market share
low cost

Significant discount
to fair value.
Under researched. Out of favour. Hidden value.
Cashflow generation OR strong balance sheets.
Quality of management. Aligned incentive structure.

Want monthly fund updates and investment insights?

PERFORMANCE

  • CHART
  • TABLE
  • UNIT PRICES

Net performance figures are shown after all fees and expenses, and assume reinvestment of distributions. Performance figures are calculated using net asset values after all fees and expenses, and assume reinvestment of distributions.  No allowance has been made for buy/sell spreads.  Please refer to the PDS for information regarding risks. Past performance is not a reliable indicator of future performance, the value of investments can go up and down.

Fund inception date Class A: December 2014, Class B July 2020.

High Conviction Equities Fund Class A

PERFORMANCE AT 28 Nov 2025
1 MTH 1 YEAR 2 YEARS P.A. 3 YEARS P.A. 5 YEARS P.A. SINCE INCEPTION P.A.
High Conviction Equities Fund Class A -8.7% 37.1% 68.3% 45.4% 22.7% 27.9%
MSCI World Total Return Index (net, AUD) 0.1% 16.2% 23.0% 20.0% 15.6% 13.3%
RBA Cash Rate plus 3% 0.5% 6.9% 7.1% 7.0% 5.6% 5.0%

Swipe horizontally to see all columns

High Conviction Equities Fund Class B

PERFORMANCE AT 28 Nov 2025
1 MTH 1 YEAR 2 YEARS P.A. 3 YEARS P.A. 5 YEARS P.A. SINCE INCEPTION P.A.
High Conviction Equities Fund Class B -8.3% 38.2% 68.2% 45.7% 23.1% 24.5%
MSCI World Total Return Index (net, AUD) 0.1% 16.2% 23.0% 20.0% 15.6% 16.0%
RBA Cash Rate plus 3% p.a. 0.5% 6.9% 7.1% 7.0% 5.6% 5.4%

Swipe horizontally to see all columns

Net performance figures are shown after all fees and expenses, and assume reinvestment of distributions. Performance figures are calculated using net asset values after all fees and expenses, and assume reinvestment of distributions.  No allowance has been made for buy/sell spreads.  Please refer to the PDS for information regarding risks. Past performance is not a reliable indicator of future performance, the value of investments can go up and down.

Fund inception date Class A: December 2014, Class B July 2020.

Net performance figures are shown after all fees and expenses, and assume reinvestment of distributions. Performance figures are calculated using net asset values after all fees and expenses, and assume reinvestment of distributions.  No allowance has been made for buy/sell spreads.  Please refer to the PDS for information regarding risks. Past performance is not a reliable indicator of future performance, the value of investments can go up and down.

Fund inception date Class A: December 2014, Class B July 2020.

Class A

Swipe horizontally to see all columns

Class B

Swipe horizontally to see all columns

PORTFOLIO

Total portfolio holdings as at 28 Nov 2025: 19

  • TOP HOLDINGS (alphabetically)
  • Portfolio breakdown
Artrya Limited
Australia
Health Care
Artrya Ltd. develops the Salix suite of products to address coronary artery disease (CAD). It uses artificial intelligence (AI) to improve the detection and management of coronary artery disease. The company was founded by John Windsor Barrington and John Konstantopoulos on January 24, 2018 and is headquartered in West Perth, Australia.
Brazilian Rare Earths Limited
Australia
Materials
Brazilian Rare Earths Ltd. operates as a mineral exploration company. It focuses on the discovery and development of mineral resources in Brazil. The company was founded on March 3, 2021 by Bernardo da Veiga and is headquartered in Sydney, Australia.
Clarity Pharmaceuticals Ltd.
Australia
Health Care
Clarity Pharmaceuticals Limited operates as a radio-pharmaceutical company. The Company focuses on the developing targeted therapies for the treatment of cancer and other serious diseases. Clarity Pharmaceuticals serves customers worldwide.
Iperionx Ltd.
Australia
Materials
IperionX Ltd. engages in the development of low carbon titanium for advanced industries, including space, aerospace, electric vehicles and 3D printing. It produces titanium metal powders from titanium scrap at its operational pilot facility in Utah and intends to scale production at a Titanium Demonstration Facility in Virginia. The company was founded on May 5, 2017 and is headquartered in Charlotte, NC.
Metallium Limited
Australia
Materials
MTM Critical Metals Ltd. engages in mineral exploration and metal recovery technology development. It focuses on the Flash Joule Heating metal extraction technology, an advanced electro-thermal process that uses rapid, high-temperature electrical pulses to facilitate metal recovery from waste streams and mineral ores. The company was founded on November 13, 2020 and is headquartered in West Perth, Australia.

Allocations may not sum to 100% due to rounding.

THE TEAM

James McDonald

James McDonald

Portfolio Manager

Read full profile >
Jeremy Bendeich

Jeremy Bendeich

Portfolio Manager

Read full profile >

Fund Facts

MINIMUM INVESTMENT:

$10,000

RECOMMENDED TIMEFRAME:

7 or more years

INCEPTION DATE:

11 December 2014

BENCHMARK:

RBA Cash Rate + 3% p.a.

MANAGEMENT AND PERFORMANCE FEES:*

Investors have the choice of:

Class A: For investors who prefer a lower performance fee with a base management fee

Management fee: 1.8%

Performance Fee: 15.38% of any return greater than the RBA’s Cash Rate target +3%, payable half-yearly

Class B: For investors who prefer a lower management fee with additional fees incurred for higher performance

Management fee: 1.25%

Performance Fee: 20% of any return greater than the MSCI
World Total Return Index (net, AUD), payable half-yearly

BUY/SELL SPREAD:

0.25%

ENTRY/ EXIT FEES:

Nil

DISTRIBUTION FREQUENCY:

Half yearly (June and December)

TYPICAL NUMBER OF STOCKS:

Typically less than 20

APIR CODE:

Class A: HHA0020AU

Class B: PCL9196AU

*Fees are stated inclusive of GST and net of RITC. For more information, refer to the Fund’s product disclosure statement available under the Reports & Resources section.

childpostid - 19327

RATINGS

childpostid - 19331

REPORTS AND RESOURCES

  • Monthly Reports
  • Financial Reports
  • Responsible Investment
  • PDS
  • Notices

NEWS AND INSIGHTS

Australia’s reigning top fund just returned 54pc in three months

Fresh off being crowned Australia’s top-performing investment strategy last year with a 109 per cent return, Pengana’s High Conviction Equities...

The Australian investors who hit the jackpot in 2024

View the original full AFR article here. It was a battle between stock pickers and cryptocurrency crusaders late last year...